Madrigal Pharmaceuticals, Inc. (LON:0JXI)

London flag London · Delayed Price · Currency is GBP · Price in USD
578.72
-11.28 (-1.91%)
At close: Dec 5, 2025
80.71%
Market Cap9.84B
Revenue (ttm)550.99M
Net Income (ttm)-215.09M
Shares Outn/a
EPS (ttm)-9.70
PE Ration/a
Forward PE126.30
Dividendn/a
Ex-Dividend Daten/a
Volume4
Average Volume54
Open593.00
Previous Close590.00
Day's Range578.41 - 593.00
52-Week Range264.12 - 605.00
Beta-0.76
RSI65.32
Earnings DateFeb 25, 2026

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
CEO William Sibold
Employees 528
Stock Exchange London Stock Exchange
Ticker Symbol 0JXI
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.